Noopur Goyal, MD
Cardiovascular Disease · Nampa, IDNPI 1568826337
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $788 of the $1,057 with a category attached, or 74.6%. 4 manufacturers reported payments, led by Boston Scientific at 48.8% of the total. That places this record below the midpoint for cardiovascular disease clinicians in ID, where the typical reported total is $1,233.
Across 41 payments — averaging $25.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$515
- Abbott$293
- Inari Medical, Inc.$173
- Edwards Lifesciences$75
What the payments were for
- Food & beverage$78875%
- Education$26925%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 36 | $515 |
| Abbott | 3 | $293 |
| Inari Medical, Inc. | 1 | $173 |
| Edwards Lifesciences | 1 | $75 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,057 in reported general payments places this provider in the 45th percentile of 59 cardiovascular disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 98 | $112,995 |
| JardianceEmpagliflozin | 57 | $69,283 |
| FarxigaDapagliflozin Propanediol | 20 | $22,523 |
| Praluent PenAlirocumab | 11 | $5,591 |
| Metoprolol Succinate | 185 | $1,442 |
| Bumetanide | 18 | $937 |
| Ranolazine ErRanolazine | 12 | $932 |
| Rosuvastatin Calcium | 63 | $795 |
| Atorvastatin Calcium | 94 | $659 |
| Lisinopril | 60 | $316 |
| Spironolactone | 76 | $287 |
| Ezetimibe | 28 | $282 |
| Amlodipine Besylate | 70 | $264 |
| Furosemide | 62 | $244 |
| Carvedilol | 24 | $243 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Nampa
- Peter RoanNampa$6K
- Michael CodinaNampa$3K
- Russell HamiltonNampa$671
- Graham WetherleyNampa$41
- Clint AllredNampa$19
- Randolph ByrdNampa$14
- David HinchmanBoise$324K
- Jacob DelarosaPocatello$226K
- David LaxsonKetchum$135K
- Ryan LongmorePocatello$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.